With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and ...

IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to ...

Results include 7.5% reduction in body weight from baseline at day 36 Weight loss continued to at least 4 weeks after last dose administered MET-097, incorporating Metsera’s HALO™ platform ...

Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million in venture funding. The data come from a Phase 1 trial of a drug, MET-097 ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a prominent player in the specialty pharmaceuticals sector, has been making waves in the market with its recent performance and strategic initiatives ...

View Amneal Pharmaceuticals, Inc. (AMRX) current and estimated P/E ratio data provided by Seeking Alpha.

Sept 23 (Reuters) - Amneal Pharmaceuticals (AMRX.O), opens new tab has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to pharmacies. In a complaint ...

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has announced the FDA approval of its Abbreviated New Drug Application (ANDA) for Propofol Injectable Emulsion in various dosages. This ...